Apotea stock
APOTEA.STSTOApotea AB, Consumer CyclicalISIN SE0023313762
72Score 72 out of 100, Strong
Price and trend
82 / 100
Price history
+9.7% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 36% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 6.1% below its 52-week high. Largest decline in 2 years: 54% (July 2025 to March 2026).
Chart figures for advanced users
- SMA 50$8.76
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.60
- The lowest closing price of the last twelve months.
- Resistance$10.70
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Apotea AB belongs to the Specialty Retail industry (Sweden) and, with a market value of $1.05B, is number 65 of 86 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $725.28M (up 10.1% year on year) and earnings of $23.03M (up 6.4%).
- MEQIRI Score 72 out of 100 (Strong): rank 116 of 602 in Consumer Cyclical, median 61.
Show more
- The P/E is 40.2 (Specialty Retail median 23, own median of recent years 41.1).
- Our model puts fair value at $8.31, with the price 23% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 37.5% in fiscal 2025, Specialty Retail median 8.1%.Profitability 66
- Earnings per share growingUp 22.1% a year since 2021.Growth 72
- Analysts expect strong earnings growthUp 18.7% a year through 2028 (estimates from 2 analysts).Growth 72
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 72.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.39 and expensive above $11.87 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $10.87 (cash-flow model) and $5.75 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $7.31, at 6.2% it would be $9.80.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (23).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.2% on the twelve months before. Revenue has grown strongly since 2021, at around 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 27%, operating 4%, net 3%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $0.08 (expected $0.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.280.0%
- Revenue
- $811.72M0.0%
- Earnings per share
- $0.350.0%
- Revenue
- $912.66M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Apotea
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
602 rated companies in Consumer Cyclical
- This company
- 72
- Sector median
- 61
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Specialty Retail
The next larger and next smaller companies by market value
- New Wave GroupNEWA-B.ST $1.4B65
- RustaRUSTA.ST $1.23B65
- MarineMaxHZO $1.17B42
- Fnac DartyFNAC.PA $1.14B52
- D-Market Elektronik Hizmetler ve Ticaret A.S.HEPS $985.94M47
- WinmarkWINA $979.35M68
- DouglasDOU.DE $921.49M43
- Cewe Stiftung & Co. KGaACWC.DE $880.36M75
ETFs that hold Apotea
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.48% | 0.68% | €5.31M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.07% | 0.38% | €86.74M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.06% | 0.23% | €319.31M |
Show 5 more
| iShares Digitalisation UCITS ETF2B79 | 0.03% | 0.40% | €726.22M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.03% | 0.30% | €3.43B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.02% | 0.39% | €1.47B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €810.11M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.